Headlines
-
Typhoid patch pursued
Monday | Aug 28 2023VAXXAS has been awarded $5.4m by global charitable foundation, Wellcome, to pursue a Phase I clinical study, with a potential second-generation typhoid vaccine, delivered by Vaxxas' proprietary high-density microarray patch (HD-MAP).
-
National awards its best
Friday | Aug 25 2023NATIONAL Pharmacies has recognised pharmaceutical organisation Viatris for ethical excellence with three different Supplier of the Year awards.
-
WholeLife collaboration
Friday | Aug 25 2023WHOLELIFE Pharmacy & Healthfoods and One Health Clinics have entered into a new business partnership for wellness solutions (PD breaking news yesterday).
-
Raising funds for next Canberra rally
Thursday | Aug 24 2023THE Community And Pharmacy Support Group (CAPS) is attempting to raise funds to hold their next rally against the 60-Day Dispensing policy, in Canberra at Parliament House, on 04 Sep.
-
Editor’s Choice: Creamy suede that dries as matte with no fade
Thursday | Aug 24 2023The Revlon ColorStay Suede Ink Lipstick aims to deliver vivid matte colour that lasts up to eight hours.
-
Corum to rebrand as PharmX Limited
Thursday | Aug 24 2023LISTED pharmacy technology specialist Corum Health has confirmed that once the sale of its software business to Canada's Jonas Group is completed (PD 24 Jul), the company plans to change its name to PharmX Technologies Limited, reflecting the success of and focus on the fast-growing PharmXchange business.
-
EBOS pharmacy revenue jumps 13.5%
Wednesday | Aug 23 2023EBOS Healthcare this morning released its results for the 12 months to 30 Jun, with overall revenue of $12.2 billion and a 25% increase in net profit after tax which increased to $253.4 million.
-
Keytruda listing for TNBC on the cards
Wednesday | Aug 23 2023BREAST Cancer Network Australia (BCNA) has welcomed a decision to recommend a crucial drug to treat early-stage triple-negative breast cancer (TNBC) for the Federal Government subsidy.
-
Drug shortage continues
Wednesday | Aug 23 2023THE pharmaceutical company Boehringer Ingelheim (BI) has notified the TGA that the shortage of its thrombolytic product, tenecteplase, is set to continue.
-
Stigma a real pain in accessing care
Wednesday | Aug 23 2023THE National Pain Survey 2023 findings have revealed a concerning correlation between chronic pain and mental health challenges, including an increased prevalence of suicidal ideation.
